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1528-4050 Copyright  2018 Woltea b aXiaoli Meng , Daniel Yerly , and Dean J. NaisbittPurpose of review
Delayed-type or nonimmediate drug hypersensitivity reactions often involve the activation of drug-specific
T cells. As such, the molecular initiating event is an interaction between HLA proteins, HLA-binding peptides
and the drug. For many years, the formation of covalently modified drug protein adducts was assumed to
be a prerequisite for T-cell activation. The purpose of this article is to review recent studies using human
PBMC, T-cell lines and clones, which show that drugs are in fact loaded onto HLA molecules in different
forms to activate T cells.
Recent findings
We now know that protein-reactive drugs such as b-lactam antibiotics activate T cells via direct noncovalent
interactions with HLA or HLA-binding peptides, direct covalent modification of HLA-binding peptides and
covalent binding of non-HLA associated proteins. Adducts formed inside and outside of the cells undergo
protein processing to generate HLA-binding peptides that are assumed to contain the drug modification.
Studies using synthetic stable (e.g. oxypurinol) and reactive (e.g. nitroso sulfamethoxazole) metabolites
show that metabolites activate T cells via the same pathways. A variety of drugs with different structural
features have also been shown to activate T cells though a direct HLA-binding interaction. Of note,
abacavir behaves in an unexpected way, binding deep in the peptide binding cleft of one HLA, selectively
activating CD8þ T cells.
Summary
In-vitro studies have revealed that a number of drug HLA-binding interactions lead to the activation of
T cells. These can be categorized according to two hypotheses, namely hapten and pharmacological
interactions. As we move forward with the development of diagnostic and predictive T-cell assays, it is
critical to reach a consensus that direct drug HLA binding and the formation of drug protein adducts are
important events for T-cell activation.
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Delayed-type drug hypersensitivity reactions target-
ing skin and internal organs remain an important
clinical problem and an obstacle to the drug devel-
opment process. The lack of effective tools to predict
which compounds will be associated with a high
frequency of reactions relates to the fact that sus-
ceptibility is a function of the chemistry of the drug
and the genotype and phenotype of the patient. In
terms of patient genotype, the expression of specific
human leukocyte antigen (HLA) alleles are known to
predispose individuals to certain forms of drug
hypersensitivity. The association between flucloxa-
cillin-induced liver injury and expression of the HLA
class I allele B57:01 is one of the most widely
studied [1]. Flucloxacillin interacts with the protein
encoded by HLA-B57:01 to activate CD8þ T cells inht © 2018 Wolters Kluwe
rs Kluwer Health, Inc. All rights resepatients with liver injury and all healthy donors.
Thus, 100% of HLA-B57:01þ individuals have a T-
cell repertoire for flucloxacillin [2–4]. Despite this,
only 1 in 1000 HLA-B57:01þ patients exposed to
flucloxacillin develop liver injury. This indicates
that there are additional yet to be defined genetic
or phenotypic differences that overlay the HLAr Health, Inc. All rights reserved.
rved. www.co-allergy.com
KEY POINTS
 Triggering of T lymphocytes from patients with drug
hypersensitivity involves the formation of a complex
between the drug, HLA molecule and HLA-binding
peptide.
 Drugs interact with HLA molecules and HLA-binding
peptides through covalent and noncovalent
binding interactions.
 Herein we review advances in our understanding of
the way in which drugs interact with HLA molecules to
activate T cells.
Drug allergyassociation and determine the outcome of drug
exposure be it immunological ignorance, tolerance
or hypersensitivity. This topic is discussed in detail
elsewhere in this edition of the journal.
One of the major controversies in the fieldofdrug
hypersensitivity is the mode of drug HLA binding
that leads to the activation of T cells. Landsteiner and
Jacobs [5] in the 1930s discovered a relationship
between the reactivity of simple chemicals and their
ability to sensitize experimental animals. This led to
the evolution of the hapten hypothesis for drug
hypersensitivity reactions, which states that reactive
drugs or drug metabolites (haptens) must bind cova-
lently to proteins to initiate immune reactions. This
hypothesis has a body of supportive evidence. For
example, IgG and IgE antibodies from plasma of
patients with hypersensitivity reactions to drugs such
as b-lactam antibiotics and halothane bind to drug-
protein adducts, but not the native protein [6,7].
Although IgG antibodies are not always pathogenic
[8], it does prove that the immune system is respond-
ing to drug-protein adducts. Expansion of the hapten
concept to T-cell-mediated drug reactions was a logi-
cal step. Proteins are naturally processed into peptide
fragments, the peptides bind to HLA molecules and
are displayed to T cells on the surface of antigen-
presenting cells. Hapten theory suggests that T cells
are activated with HLA-bound peptides that contain
the hapten bound covalently to nucleophilic sites on
amino acids such as cysteine and lysine.
Our understanding of the chemical basis of drug
hypersensitivity reactions improved, but became
much more complicated, when researchers found
that certain drugs interact directly with HLA mole-
cules or HLA-binding peptides. This led to evolution
of the pharmacological interactions hypothesis,
which states that a direct, readily reversible interac-
tion of drug with HLA will activate T cells (i.e.
binding of drug to the immune receptor [HLA],
results in unexpected and unwanted secondary
pharmacology that manifests as hypersensitivity). Copyright © 2018 Wolters Kluwer 
318 www.co-allergy.comHerein, we summarize recent advances in our
understanding of the hapten and pharmacological
interactions hypotheses with reference to T-cell-
mediated drug hypersensitivity. We now know that
drugs and drug haptens interact with HLA in differ-
ent ways, and this has resulted in exciting new
concepts. However, these data should enhance
and not confuse or complicate our mechanistic
understanding. The fact remains that drugs bind
to HLA via covalent or noncovalent bonds, and as
such, only two fundamental hypotheses are
required for drug-specific T-cell activation – hapten
and pharmacological interactions. These are dis-
cussed below.HAPTEN HYPOTHESIS
The consequences of drug-protein adduct
formation
Haptens are small molecules that can covalently
bind to proteins either directly or via drug metabo-
lism. The major protein targets for the directly reac-
tive haptens could be serum proteins such as
albumin and haemoglobin, intracellular proteins
or specific tissue proteins depending on the routes
of administration and the accumulation in specific
tissues. The detection of amoxicillin-modified intra-
cellular proteins through use of a biotinylated anti-
biotic could be of particular importance [9]. In
contrast, protein targets for the reactive metabolites
could vary greatly depending on the sites of forma-
tion and their chemical reactivity, though liver
proteins may be the major targets for many reactive
metabolites because of its primary metabolic func-
tion. For example, the cytochrome P450 enzymes
are targeted by many short-lived reactive metabo-
lites, and haptenation of these proteins can lead to
both drug-specific and auto-immune responses [10].
Stable metabolites that are able to escape from the
liver can also haptenate circulating proteins, for
example, carbamazepine 10–11 epoxide was found
to bind to albumin in patients receiving carbamaze-
pine therapy [11]. Both haptenic structures and
carrier proteins are vital for T-cell and antibody
recognition, however, haptenic structures have a
dominant role in both events. For instance, piper-
acillin forms two distinct haptens in patients by
conjugation with the lysine residues of albumin,
one formed directly from piperacillin and a second
in which the dioxopiperazine ring has undergone
hydrolysis [12]. These haptens are able to stimulate
the T cells of patients with piperacillin hypersensi-
tivity. Flucloxacillin also binds to the same lysine
residues on albumin as piperacillin, but the resulting
conjugates do not stimulate the piperacillinHealth, Inc. All rights reserved.
Volume 18  Number 4  August 2018
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ing that the drug conjugates have structural speci-
ficity [13]. In addition, no cross-reactivity was
observed between antipiperacillin and antifluclox-
acillin IgG antibodies, providing further evidence
that the immune responses to drugs are highly
structurally specific. It is, therefore, absolutely vital
to characterize the exact haptenic structures if we
are to understand the molecular mechanisms of
drug hypersensitivity.
Nowadays, advanced mass spectrometric-based
proteomic methods have allowed us to not only
identify protein targets and the specific sites where
the haptens bind to but to also characterize com-
plex antigenic structures formed in vivo. For exam-
ple, both amoxicillin and its dimer were found to
form adducts on albumin in patients, and clavu-
lanic acid formed multiple adducts on albumin
through several degradation intermediates [14].
We and others have shown that clavulanic acid
rapidly undergoes hydrolysis in plasma and forms
multiple degradation products [14,15]. Adducts
including those formed by direct binding of clav-
ulanic acid to lysine residues, a cross-linking
adduct, and pyrazine adducts were identified by
mass spectrometric analysis. All these adducts
could have potential to stimulate specific B and/
or T cells. Considerable progress has been made on
the characterization of haptenated proteins, but
the functions of these antigens in drug hypersen-
sitivity remain largely unexplored. A limited num-
ber of drug-modified proteins have been shown to
stimulate drug-specific T cells via a pathway depen-
dent on protein processing [16,17
&&
]. Synthetic
peptides designed to bind to specific HLA mole-
cules and modified covalently with drugs also
stimulate a T-cell response [18
&&
,19]. Furthermore,
synthetic reactive drug metabolites activate T cells
through the direct covalent modification of HLA-
binding peptides or HLA itself and the formation of
adducts with non-HLA-associated protein (Fig. 1)
[20,21]. The latter is dependent on protein proc-
essing to generate HLA-binding peptides. It is
worth noting that the formation of drug antigens
may be important for initiating an immune
response, but this process alone will not always
result in hypersensitivity. Indeed, circulating drug-
modified proteins have been detected in patients
without hypersensitivity [17
&&
]. Furthermore, all
individuals express T-cell receptors (TCRs) that
detect drug-modified peptides [18
&&
]. Therefore,
the critical question remains, what determines
immunity? The consistent exposure to drug anti-
gens, the maintenance of immune activation by
costimulatory signals, or the inhibitory signals that
regulate the immune responses? Any of these Copyright © 2018 Wolters Kluwe
1528-4050 Copyright  2018 Wolters Kluwer Health, Inc. All rights resefactors may be important in determining the over-
all immune response.Processing and presentation of haptenated
proteins
Intracellular processing of protein antigens to pep-
tides followed by presentation of peptide-HLA com-
plexes by professional antigen-presenting cells such
as dendritic cells and B cells is essential for initiating
T-cell responses to infectious pathogens. Compre-
hensive methods have been developed to evaluate
the identities and densities of peptides presented by
antigen-presenting cells to address the relationship
between peptide display by HLA molecules and
antigen-specific T-cell responses. For example, pro-
filing of peptides presented by HLA-class I molecules
has highlighted a mechanism through which a
polymorphism within an HLA supertype can diver-
sify immune responses by varying peptide length
preferences [22]. However, how adduction of hapt-
ens to proteins affects the processing of proteins and
the presentation of haptenated peptides remains
unknown. One possible pathway of presenting
drug–peptide conjugates is through intracellular
processing of haptenated proteins. It is anticipated
that haptenation could have profound effect on the
complex antigen-processing cascade. For example,
covalent binding of haptens to specific amino acid
residues, for example, cysteine, serine, lysine or
arginine could block the enzymatic processing by
cytoplasmic proteases, which could result in gener-
ating different peptides of various lengths compared
with the counterpart without modification. In addi-
tion, haptenation of basic amino acids could affect
the peptide-binding affinity to the transporter asso-
ciated with antigen processing (TAP) [23], thereby
creating structurally distinct peptide–HLA com-
plexes. Alternatively, direct haptenation of the pep-
tide–HLA complex could also occur. In this
scenario, the selectivity of covalent binding will
be determined by the surface exposure and intrinsic
reactivity of an amino acid and the presentation of
drug–peptide conjugates will be independent of
peptide-HLA binding affinity. Finally, haptenation
of HLA itself could lead to altered peptide presenta-
tion through covalent binding to the peptide bind-
ing groove or even allosteric sites. It should be noted
the position of hapten binding may alter the TCR
contact sites on the HLA molecule, and thereby play
an important role in T-cell activation. Despite exten-
sive research in this field, drug–peptide conjugates
presented by antigen-presenting cells have not been
reported yet, possibly because of the technical chal-
lenges of identifying them. The lack of knowledge
has greatly hindered the understanding of howr Health, Inc. All rights reserved.
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FIGURE 1. Possible pathways of presenting haptenated peptides to T cells. (a) Processing dependent: haptens (small drugs
and chemicals) can covalent bind to proteins that are processed intracellularly and presented by APCs in the context of MHC
molecules; (b) Processing independent: they can directly bind to either MHC–peptide complex or MHC molecules, leading to
alteration of either the conformation of MHC–peptide complex or the presentation of the self-peptide repertoire.
Drug allergyhaptens initiate T-cell responses. Continuing efforts
to characterize haptenated peptides presented by
specific HLA alleles and to examine their immuno-
genicity will certainly shed light on the molecular
mechanisms underlying T-cell activation.
In addition to antigen presentation by direct
cell–cell contacts, the intact peptide–HLA complex
can also be transferred and presented intercellularly
through extracellular vesicles. This process involves
the acquisition of entire peptide–HLA complexes
from a donor cell, supplementing cross-presenta-
tion pathways [24]. This can occur between Copyright © 2018 Wolters Kluwer 
320 www.co-allergy.comantigen-presenting cells or antigen-presenting cells
and other target cells. We and others have recently
shown that exosomes released by primary human
hepatocytes and B cells contain peptide–HLA com-
plexes and drug-modified proteins [25
&&
]. The exo-
somes can be up-taken by dendritic cells, providing
an additional pathway for the transfer of tissue-
specific drug-derived antigenic signals to immune
cells (Ogese et al., unpublished data). It is possible
that the transfer of peptide–HLA complexes
between target cells and antigen-presenting cells is
of great importance and may play a role in drug-Health, Inc. All rights reserved.
Volume 18  Number 4  August 2018
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characterization of peptide–HLA complexes present
in exosomes will certainly improve our fundamental
understanding of the molecular mechanisms of
antigen presentation. This knowledge will also allow
us to further investigate the communications
between target cells and immune cells.
It is important to mention that the innate
immune system is critical in initiating or silencing
T-cell responses. For example, under noninflamma-
tory environment, immature dendritic cells can
modulate tolerant responses by induction of anergy,
T-regulatory cells, or immunomodulatory cyto-
kines; whereas mature dendritic cells stimulated
by inflammatory signals, drugs, or drug-proteins
adducts can efficiently prime naı¨ve T cells and
induce the development of T-effector cells [26,27].
A recent study has shown that amoxicillin can
change the steady state of dendritic cells, from
hypersensitivity patients but not controls, leading
to a degree of maturation [28]. Although the exact
mechanisms of triggering the dendritic cell matura-
tion by drugs remain to be determined, activation of
MAPK and NF-kB signalling by amoxicillin is
thought to be involved in dendritic cell maturation
[29]. Further studies on drug–dendritic cell interac-
tions will help establish the threshold of T-cell
activation and tolerance.The pharmacological interactions concept
The pharmacological interaction concept stands for
pharmacological interaction with immune recep-
tors and stipulates that a small molecular compound
can interact with the TCR-major histocompatibility
complex (MHC) complex by noncovalent interac-
tions. If such interactions are strong enough, the
stabilization of the complex leads to the activation
of the T cell. For the pharmacological interaction
concept, covalent modifications of proteins are not
a prerequisite for the generation of the antidrug T-
cell response. The pharmacological interaction con-
cept arose around 20 years ago from the observation
that drug-reacting T-cell clones (TCC) did not
always follow the rules of T-cell activation by
haptenated proteins [30]. Indeed, lidocaine or sul-
famethoxazole reacting TCC, which were isolated
from drug hypersensitive patients were activated
only in the presence of the soluble drugs. Washing
of antigen presenting cell (APC) preincubated with
drugs abrogated the T-cell activation, showing that
the antigen complex was not stable. Moreover, in
the pharmacological interaction mechanism, the
inhibition of either the endogenic or the hexogenic
antigen presentation pathway did not influence the
activation of drug reacting T cells in the opposite to Copyright © 2018 Wolters Kluwe
1528-4050 Copyright  2018 Wolters Kluwer Health, Inc. All rights resehaptenated proteins. Indeed, the proteasome inhi-
bition did not reduce the stimulation of CD8þ T-cell
clones recognizing soluble flucloxacillin on HLA-
B57:01 molecules (Fig. 2). In contrast, when flu-
cloxacillin was recognized by the hapten mecha-
nism, proteasome inhibition abrogated the T-cell
activation. In addition, it has been shown that even
paraformaldehyde fixed APC were able to present
drugs following thepharmacological interaction
mechanism [31], showing the complete indepen-
dence of pharmacological interaction mechanism
toward the antigen processing pathways. Finally,
the pharmacological interaction mechanism could
be revealed by the activation kinetics of drug-react-
ing TCC. Whereas the presentation of haptenated
proteins is time consuming (minutes to hours),
intracellular calcium concentration increases imme-
diately after the addition of the soluble drug into the
cell culture and peaks within seconds [32].The interaction partners in the
pharmacological interaction concept
In drug-reacting T cells following the pharmacolog-
ical interaction mechanism, all the interactions
partners, that is, HLA molecule, the embedded pep-
tide, the TCR and the drug are vital for T-cell activa-
tion, however, the drug plays a dominant role.
Whereas the absence of any of the interactions,
partner would abrogate the T-cell activation, only
the addition of the drug triggers the reaction, as
exemplified in calcium influx assay (see above).
Drug reacting pharmacological interaction TCC
were shown to be HLA restricted [30]. In the major-
ity of the cases, CD4þ T cells are MHC class II
restricted and CD8þ T cells are MHC class I
restricted. Nevertheless, it is not uncommon to
observe unconventional HLA restriction, a CD8þ
TCC being MHC class II restricted for instance
[33]. Although the majority of the TCC are also
HLA allele restricted [34], it has been assessed that
roughly one fourth of the drug-reacting T cells were
not HLA allele restricted. However, this feature
could not be observed in HLA-associated drug
hypersensitivity reactions, such as abacavir and
HLA-B57:01, allopurinol and HLA-B58:01 or car-
bamazepine and HLA-B15:02. Here, tiny modifica-
tions of the restricting presenting HLA allele were
shown to abolish the reactivity [35]. In the case of
abacavir, crystals could be generated and revealed
the drug-binding site within the peptide-binding
groove of the HLA-B57:01 [36–38]. Of note, the
interactions between abacavir, the HLA molecule
and the peptide were purely noncovalent, demon-
strating the pharmacological interaction properties
of this association. The van der Waals interactionsr Health, Inc. All rights reserved.
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FIGURE 2. Possible pathways of presenting drug directly to T cells via the pharmacological interaction mechanism. (a) Drug
interacts preferentially with the T-cell receptor; (b) drug interacts preferentially with the HLA leading to either altered
antigenicity of the same peptide or binding of novel peptides. HLA, human leukocyte antigen.
Drug allergybetween abacavir and the f-pocket are strong
enough that it resists washing steps. This feature
could not be reproduced for other drugs with similar
HLA associations like flucloxacillin on HLA-B57:01 Copyright © 2018 Wolters Kluwer 
322 www.co-allergy.comor oxypurinol on HLA-B58:01, for which interac-
tions are very labile and do not sustain APC wash-
ings [4,32]. On MHC class I molecules, the C-
terminal of the embedded peptide interacts withHealth, Inc. All rights reserved.
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Mechanisms leading to T-cell activation Meng et al.the f-pocket to stabilize the peptide within the pep-
tide groove, so that peptides with a Tyr or a Phe at
their C-terminal are favoured in HLA-B57:01 mole-
cules. In the presence of abacavir, the space and
properties of the f-pocket are modified so that smaller
and aliphatic residues are preferred, like Leu or Ile.
This leads to the presentation of a new set of endoge-
nous peptides, which are not supposed to be pre-
sented by HLA-B57:01. Of note this new set of
presented peptides were never subjected to the thy-
mic negative selection. To our knowledge, abacavir is
the only known drug, which is able to modify the
peptide-binding properties of HLA molecules. This
feature could not be observed for other drugs such as
flucloxacillin, oxypurinol or carbamazepine [39].
Thus, the presentation of another set of peptides
cannot be generalized to other HLA-associated drug
hypersensitivity reactions. Docking analysis suggest
that oxypurinol binds within the f-pocket of HLA-
B58:01, although alterations in the peptide reper-
toire displayed by HLA-B58:01 in the presence of
oxypurinol have thus far not been observed. It is
thought that oxypurinol can modify the shape of
the presented peptide, altering its antigenic proper-
ties [32]. This proposition arose from the observation
that oxypurinol TCC were immediately activated
after the addition of oxypurinol in the cell culture,
a process too rapid for a putative peptide exchange.
For that matter, such a mechanism cannot be
excluded for abacavir either, as similar activation
kinetics can be observed in abacavir reacting TCC
[40]. In the case of HLA-B15:01-restricted carbamaz-
epine-induced Stevens–Johnson syndrome, a partic-
ular TCR fragment of the TCR repertoire has also been
detected [41]. Ko et al. could find in PBMC from
affected patients that the vast majority of carbamaz-
epine activated T cells were monoclnal or oligoclo-
nal, carrying the Vb-11 segment. In contrast, this
particular clonotype could not be found in carbamaz-
epine-tolerant patients, carrying the HLA-B15:02
molecules. Such well defined associated clonotype
could, however, not be detected in other HLA-asso-
ciated drug hypersensitivity so far.The consequences of the pharmacological
interaction concept on the priming of a T-cell
response
Explaining how interactions lead to TCR activation
does not clarify how a T-cell response to drugs arises.
According to textbook knowledge, two signals, that is,
antigen and danger signals are necessary for the prim-
ing of an immune response. In many contact derma-
titis models, the important role of dendritic cell
maturation has been well studied and confirmed for
haptens [42]. However, drug-reacting T cells following Copyright © 2018 Wolters Kluwe
1528-4050 Copyright  2018 Wolters Kluwer Health, Inc. All rights resethe pharmacological interaction mechanism can be
expanded in the absence of danger signals from the
innate immune system. It has been shown that aba-
cavir-reacting T cells could be primed in vitro without
dendritic cell maturation in drug naı¨ve individuals. It
was even possible to generate such cells in the absence
of dendritic cells or monocytes [43], arguing against
the need of co-stimulatory signals in the primary
response to drugs following the pharmacological
interaction mechanism. An explanation for this fea-
ture could suggest that the reacting T cells originated
from the memory compartment. It is hypothesized
that pharmacological interaction reacting T cells
could be cross-reactive with antigenic peptides from
microorganisms representing the infectious history of
the drug hypersensitive patients. Although a recent
study tackled this hypothesis [38], a formal proof has
not been discovered yet. Nevertheless, drug reacting
cells canbegenerated from thememoryas wellas from
the naı¨ve pool of T cells in drug-naı¨ve individuals.EXPERT CONCLUSION AND FUTURE
PERSPECTIVE
It is now absolutely clear that drugs and drug hapt-
ens activate human naı¨ve and memory T cells.
Future research should attempt to determine the
contribution of the hapten and pharmacological
interaction hypotheses in different forms of drug
hypersensitivity. This will be complicated by the
fact that the same patient often has T cells that
are activated via both pathways. Furthermore, a
single cloned T cell has been shown to be activated
with the parent drug and a reactive metabolite via
different pathway [20,21].
Prediction of the immunogenic potential of new
chemical entities is incredibly difficult as any
approach must include assessment of adduct forma-
tion and the display of haptenated peptides on HLA
and direct drug HLA binding. Simple chemical reac-
tivity screens have their usefulness, however, many
drugs that form reactive metabolites are not associ-
ated with a high incidence of hypersensitivity. More-
over, the almost limitless number of drug hapten and
drug-binding sites reduces the effectiveness of simple
HLA-binding assays. The vision for the future should
be a simplified T-cell assay capable of screening mul-
tiple compounds in a single assay. Incorporation of a
drug hapten-generating system would be an impor-
tant feature. In this respect, new culture plates where
tissue and immune cells are separated, but exposed to
the same medium offer some hope. The tissue cells
will generate soluble metabolites and exosomes con-
taining encapsulated protein adducts that will be
transferred to antigen-presenting cells, prior to proc-
essing and presentation to T cells.r Health, Inc. All rights reserved.
rved. www.co-allergy.com 323
Drug allergyAcknowledgements
None.
Financial support and sponsorship
The work was supported by theMedical Research Council
Centre for Drug Safety Science (Grant Number MR/
L006758/1, XM) and by the Ulrich M€uller-Gierok foun-
dation.
Conflicts of interest
There are no conflicts of interest.REFERENCES AND RECOMMENDED
READING
Papers of particular interest, published within the annual period of review, have
been highlighted as:
& of special interest
&& of outstanding interest1. Daly AK, Donaldson PT, Bhatnagar P, et al.,DILIGENStudy; International SAE
Consortium. HLA-B5701 genotype is a major determinant of drug-induced
liver injury due to flucloxacillin. Nat Genet 2009; 41:816–819.
2. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-
B57:01-restricted activation of drug-specific T cells provides the immunological
basis for flucloxacillin-induced liver injury. Hepatology 2013; 57:727–739.
3. Yaseen FS, Saide K, Kim SH, et al. Promiscuous T-cell responses to drugs
and drug-haptens. J Allergy Clin Immunol 2015; 136:474.e8–476.e8.
4. Wuillemin N, Adam J, Fontana S, et al.HLA haplotype determines hapten or p-
i T cell reactivity to flucloxacillin. J Immunol 2013; 190:4956–4964.
5. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple
chemical compounds. J Exp Med 1935; 61:643–656.
6. Kenna JG, Knight TL, van Pelt FN. Immunity to halothane metabolite-modified
proteins in halothane hepatitis. Ann N Y Acad Sci 1993; 685:646–661.
7. Christie G, Coleman JW, Newby S, et al. A study of the prevalence of
penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined
by hapten inhibition, in patients with suspected penicillin allergy and in healthy
volunteers. Br J Clin Pharmacol 1988; 25:381–386.
8. Lopez S, Blanca-Lopez N, Cornejo-Garcia JA, et al. Nonimmediate reactions
to betalactams. Curr Opin Allergy Clin Immunol 2007; 7:310–316.
9. Ariza A, Collado D, Vida Y, et al. Study of protein haptenation by amoxicillin
through the use of a biotinylated antibiotic. PLoS One 2014; 9:e90891.
10. Metushi IG, Sanders C, Acute Liver Study Group, et al. Detection of anti-
isoniazid and anticytochrome P450 antibodies in patients with isoniazid-
induced liver failure. Hepatology 2014; 59:1084–1093.
11. Yip VLM, Meng X, Maggs JL, et al. Mass spectrometric characterization of
circulating covalent protein adducts derived from epoxide metabolites of
carbamazepine in patients. Chem Res Toxicol 2017; 30:1419–1435.
12. Whitaker P, Meng X, Lavergne SN, et al.Mass spectrometric characterization
of circulating and functional antigens derived from piperacillin in patients with
cystic fibrosis. J Immunol 2011; 187:200–211.
13. El-Ghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen
specificity of T-cell clones from piperacillin-hypersensitive patients with cystic
fibrosis. J Pharmacol Exp Ther 2012; 341:597–610.
14. Meng X, Earnshaw CJ, Tailor A, et al. Amoxicillin and clavulanate form
chemically and immunologically distinct multiple haptenic structures in pa-
tients. Chem Res Toxicol 2016; 29:1762–1772.
15. Torres MJ, Montanez MI, Ariza A, et al. The role of IgE recognition in allergic
reactions to amoxicillin and clavulanic acid. Clin Exp Allergy 2016;
46:264–274.
16. Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell re-
sponses to beta-lactam-modified self-structures are observed in penicillin-
allergic individuals. J Immunol 1995; 155:2670–2678.
17.
&&
Meng X, Al-Attar Z, Yaseen FS, et al. Definition of the nature and hapten
threshold of the beta-lactam antigen required for T Cell activation in vitro and
in patients. J Immunol 2017; 198:4217–4227.
A quantitative analysis of drug protein binding in patients. The level of binding in
tolerant and allergic patients does not differ. Furthermore, the level of binding in
patients exceeds that required to activate T cells in vitro. Copyright © 2018 Wolters Kluwer 
324 www.co-allergy.com18.
&&
Azoury ME, Fili L, Bechara R, et al. Identification of T-cell epitopes from
benzylpenicillin conjugated to human serum albumin and implication in
penicillin allergy. Allergy 2018. [Epub ahead of print]
This manuscript show that virtually all healthy individuals possess a T-cell repertoire
to beta-lactam peptide conjugates derived from albumin.
19. Padovan E, Bauer T, Tongio MM, et al. Penicilloyl peptides are recognized as T
cell antigenic determinants in penicillin allergy. Eur J Immunol 1997;
27:1303–1307.
20. Elsheikh A, Castrejon L, Lavergne SN, et al. Enhanced antigenicity leads to
altered immunogenicity in sulfamethoxazole-hypersensitive patients with cys-
tic fibrosis. J Allergy Clin Immunol 2011; 127:1543.e3–1551.e3.
21. Castrejon JL, Berry N, El-Ghaiesh S, et al. Stimulation of human T cells with
sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 2010;
125:411.e4–418.e4.
22. Rist MJ, Theodossis A, Croft NP, et al. HLA peptide length preferences
control CD8þ T cell responses. J Immunol 2013; 191:561–571.
23. Procko E, Gaudet R. Antigen processing and presentation: TAPping into ABC
transporters. Curr Opin Immunol 2009; 21:84–91.
24. Lindenbergh MFS, Stoorvogel W. Antigen presentation by extracellular
vesicles from professional antigen-presenting cells. Annu Rev Immunol
2018; 36:435–459.
25.
&&
Sanchez-Gomez FJ, Gonzalez-Morena JM, Vida Y, et al. Amoxicillin hapte-
nates intracellular proteins that can be transported in exosomes to target cells.
Allergy 2017; 72:385–396.
Demonstration that drug adducts are loaded into exosomes provides new routes
for the transport of antigenic determinants to the adaptive immune system.
26. Mahnke K, Schmitt E, Bonifaz L, et al. Immature, but not inactive: the
tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;
80:477–483.
27. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells:
which signals induce tolerance or immunity? Trends Immunol 2002;
23:445–449.
28. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of
dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J
Allergy Clin Immunol 2006; 118:949–956.
29. Lopez S, Gomez E, Torres MJ, et al. Betalactam antibiotics affect
human dendritic cells maturation through MAPK/NF-kB systems. Role
in allergic reactions to drugs. Toxicol Appl Pharmacol 2015; 288:
289–299.
30. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and
metabolism-independent pathway of drug recognition by human alpha beta T
lymphocytes. J Clin Invest 1998; 102:1591–1598.
31. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to
quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006;
36:59–69.
32. Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately
activates the drug-specific T cells via the preferential use of HLA-B58:01. J
Immunol 2014; 192:2984–2993.
33. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent
presentation of the drug sulfamethoxazole to human alphabeta T cell clones.
J Clin Invest 1997; 100:136–141.
34. von Greyerz S, Bultemann G, Schnyder K, et al. Degeneracy and additional
alloreactivity of drug-specific human alpha beta(þ) T cell clones. Int Immunol
2001; 13:877–885.
35. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-
restricted activation of CD8þ T cells provides the immunogenetic basis of a
systemic drug hypersensitivity. Immunity 2008; 28:822–832.
36. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-
modified HLA-peptide repertoire. Nature 2012; 486:554–558.
37. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by
alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U
S A 2012; 109:9959–9964.
38. Yerly D, Pompeu YA, Schutte RJ, et al. Structural elements recognized by
abacavir-induced T cells. Int J Mol Sci 2017; 18:; pii: E1464.
39. YangCW,Hung SI, Juo CG, et al.HLA-B1502-bound peptides: implications
for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.
J Allergy Clin Immunol 2007; 120:870–877.
40. Adam J, Eriksson KK, Schnyder B, et al. Avidity determines T-cell reactivity in
abacavir hypersensitivity. Eur J Immunol 2012; 42:1706–1716.
41. Ko TM, ChungWH,Wei CY, et al.Shared and restricted T-cell receptor use is
crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin
Immunol 2011; 128:1266.e11–1276.e11.
42. Kaplan DH, Igyarto BZ, Gaspari AA. Early immune events in the induction of
allergic contact dermatitis. Nat Rev Immunol 2012; 12:114–124.
43. Adam J, Wuillemin N, Watkins S, et al. Abacavir induced T cell reactivity from
drug naive individuals shares features of allo-immune responses. PLoS One
2014; 9:e95339.Health, Inc. All rights reserved.
Volume 18  Number 4  August 2018
